These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 19080989)

  • 21. Methotrexate and ciclosporin combination for the treatment of severe psoriasis.
    Aydin F; Canturk T; Senturk N; Turanli AY
    Clin Exp Dermatol; 2006 Jul; 31(4):520-4. PubMed ID: 16716153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infliximab in the treatment of psoriasis in patients previously treated with etanercept.
    Haitz KA; Kalb RE
    J Am Acad Dermatol; 2007 Jul; 57(1):120-5. PubMed ID: 17482715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
    Lecha M; Mirada A; López S; Artés M;
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study.
    Voulgari PV; Venetsanopoulou AI; Exarchou SA; Alamanos Y; Tsifetaki N; Drosos AA
    Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2).
    Reich K; Wozel G; Zheng H; van Hoogstraten HJ; Flint L; Barker J
    Br J Dermatol; 2013 Jun; 168(6):1325-34. PubMed ID: 23621698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE;
    Lancet; 2005 Oct 15-21; 366(9494):1367-74. PubMed ID: 16226614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
    Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
    Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P; Del Giglio M; Cotena C; Girolomoni G
    Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice.
    Barrera MV; Habicheyn S; Mendiola MV; Herrera Ceballos E
    Eur J Dermatol; 2008; 18(6):683-7. PubMed ID: 19049936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
    Balasubramaniam P; Stevenson O; Berth-Jones J
    Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
    Feldman SR; Gottlieb AB; Bala M; Wu Y; Eisenberg D; Guzzo C; Li S; Dooley LT; Menter A
    Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
    Reich K; Nestle FO; Wu Y; Bala M; Eisenberg D; Guzzo C; Li S; Dooley LT; Griffiths CE
    Eur J Dermatol; 2007; 17(5):381-6. PubMed ID: 17673380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
    Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
    Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
    Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
    Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K; Rogers S
    Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three years' experience with infliximab in recalcitrant psoriasis.
    Ahmad K; Rogers S
    Clin Exp Dermatol; 2006 Sep; 31(5):630-3. PubMed ID: 16901301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice.
    Shear NH; Hartmann M; Toledo-Bahena M; Katsambas A; Connors L; Chang Q; Yao R; Nograles K; Popmihajlov Z;
    Br J Dermatol; 2014 Sep; 171(3):631-41. PubMed ID: 24673357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.